Literature DB >> 8959989

Role of selegiline in combination therapy of Parkinson's disease.

V V Myllylä1, K Sotaniemi, O Mäki-Ikola, U K Rinne, E H Heinonen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8959989     DOI： 10.1212/wnl.47.6_suppl_3.200s

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

1.  Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.

Authors:  A Negrotti; G Bizzarri; S Calzetti
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

2.  Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.

Authors:  K Laine; M Anttila; A Helminen; H Karnani; R Huupponen
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

Review 3.  Novel approaches to the treatment of cocaine addiction.

Authors:  Mehmet Sofuoglu; Thomas R Kosten
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

Authors:  E H Heinonen; V Myllylä
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

5.  Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

Authors:  Bradley J Robottom
Journal:  Patient Prefer Adherence       Date:  2011-01-20       Impact factor: 2.711
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.